Literature DB >> 15869722

Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?

Edith D Canby-Hagino1, Gregory P Swanson, E David Crawford, Joseph W Basler, Javier Hernandez, Ian M Thompson.   

Abstract

Data from well-designed, prospective clinical trials are lacking to support treatment of primary tumor in men diagnosed with metastatic prostate cancer. However, a growing body of evidence suggests that treatment of the primary tumor may enhance cancer control and survival in some men. This evidence is examined and recommendations are made for identifying patients with metastatic prostate cancer who may benefit from definitive treatment of the prostate tumor.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15869722     DOI： 10.1007/s11934-005-0006-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  48 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  The if and when of surgical debulking for ovarian carcinoma.

Authors:  Tate Thigpen
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.

Authors:  J M Crook; Y A Bahadur; R G Bociek; G A Perry; S J Robertson; B A Esche
Journal:  Cancer       Date:  1997-01-15       Impact factor: 6.860

4.  Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

Authors:  G K Zagars; A Pollack; A C von Eschenbach
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.

Authors:  Scott M Eisenkop; Nick M Spirtos; Richard L Friedman; Wei-Chien Michael Lin; Albert L Pisani; Sergio Perticucci
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

Review 7.  Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.

Authors:  T M Seay; M L Blute; H Zincke
Journal:  J Urol       Date:  1998-02       Impact factor: 7.450

8.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

9.  Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Authors:  Leonard L Gunderson; Daniel J Sargent; Joel E Tepper; Norman Wolmark; Michael J O'Connell; Mirsada Begovic; Cristine Allmer; Linda Colangelo; Steven R Smalley; Daniel G Haller; James A Martenson; Robert J Mayer; Tyvin A Rich; Jaffer A Ajani; John S MacDonald; Christopher G Willett; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

10.  Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate.

Authors:  R L Cox; E D Crawford
Journal:  Urology       Date:  1995-06       Impact factor: 2.649
View more
  4 in total

Review 1.  Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis.

Authors:  Arie Carneiro; Willy Baccaglini; Felipe P A Glina; Paulo P Kayano; Victor M Nunes; Oren Smaletz; Wanderley Marques Bernardo; Icaro Thiago de Carvalho; Gustavo Caserta Lemos
Journal:  Int Braz J Urol       Date:  2017 Jul-Aug       Impact factor: 1.541

2.  Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study.

Authors:  Shengming Jin; Jiaming Wei; Junjie Wang; Beihe Wang; Junlong Wu; Hualei Gan; Bo Dai; Xiaojian Qin; Guowen Lin; Yu Wei; Chen Yang; Yijun Shen; Yiping Zhu; Yao Zhu; Dingwei Ye
Journal:  Front Oncol       Date:  2020-12-08       Impact factor: 6.244

Review 3.  Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

Authors:  Pedro Leonel Almeida; Bruno Jorge Pereira
Journal:  Prostate Cancer       Date:  2018-03-19

Review 4.  Role of surgery in oligometastatic prostate cancer.

Authors:  Pocharapong Jenjitranant; Karim A Touijer
Journal:  Prostate Int       Date:  2019-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.